ELIZABETH GRANIERI
Allopathic & Osteopathic Physicians|Internal Medicine|Endocrinology, Diabetes & Metabolism GREAT NECK, NY NPI 1780975102
Browse related groups: Allopathic & Osteopathic Physicians|Internal Medicine|Endocrinology, Diabetes & Metabolism NY Novo Nordisk AS All categories
This page merges CMS profile IDs: 4154850, 5701180 (associated profiles published by CMS for the same provider; see the provenance section below).
General Payments — all program years on this page
$11,184.31
- Category: General Payments
- Program years: PY2018–2024
- Record count: 598
- As of (CMS publication): 2026-01-23
Latest program year (PY2024): $2,415.82 across 107 records · disputed records: 0
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How this figure is calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
Latest program year (PY2024) · sorted by reported total.
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $2,415.82 | 107 |
By paying entity
Latest program year (PY2024) · sorted by reported total.
| Paying entity | Amount | Records |
|---|---|---|
| Novo Nordisk AS | $446.40 | 23 |
| Lilly USA, LLC | $348.95 | 16 |
| Medtronic, Inc. | $197.23 | 6 |
| Amgen Inc. | $190.01 | 11 |
| DEXCOM, INC. | $122.50 | 2 |
| Corcept Therapeutics | $111.25 | 5 |
| BOSTON SCIENTIFIC CORPORATION | $109.67 | 1 |
| BETA BIONICS, INC. | $109.34 | 2 |
| Xeris Pharmaceuticals, Inc. | $106.31 | 5 |
| Abbott Laboratories | $94.44 | 5 |
| SANOFI-AVENTIS U.S. LLC | $90.16 | 5 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $82.91 | 5 |
| Insulet Corporation | $63.74 | 3 |
| Bayer HealthCare Pharmaceuticals Inc. | $63.35 | 3 |
| ABBVIE INC. | $51.65 | 3 |
| Tandem Diabetes Care, Inc. | $42.86 | 2 |
| MannKind Corporation | $24.01 | 1 |
| NOVARTIS PHARMACEUTICALS CORPORATION | $20.19 | 1 |
| Averitas Pharma Inc. | $18.91 | 1 |
| Amneal Pharmaceuticals LLC | $18.54 | 1 |
| PFIZER INC. | $18.53 | 1 |
| Antares Pharma, Inc. | $17.59 | 1 |
| Ascendis Pharma Inc | $17.28 | 1 |
| Sequel Med Tech, LLC | $17.12 | 1 |
| Amphastar Pharmaceuticals, Inc. | $16.55 | 1 |
| CeQur Corporation | $16.33 | 1 |
By program year
Records — PY2024 (107)
Provenance & corrections
- Dataset: CMS Open Payments — General Payments
- Source: CMS Open Payments dataset (bulk file)
- Publisher of source data: Centers for Medicare & Medicaid Services
- Generated from: OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
- Merged CMS profile IDs: 4154850, 5701180
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.